Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference | ||
By: GlobeNewswire - 23 Nov 2022 | Back to overview list |
|
CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 34th Annual Piper Sandler Healthcare Conference on Tuesday, November 29 at 2:00PM E.T. A live webcast of the presentation will be available on the Investors page of the Company’s website at investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation. About TCR2 Therapeutics TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The Company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR2, please visit www.tcr2.com. Investor and Media Contact: |
||
|
||
Copyright 2022 GlobeNewswire | Back to overview list |